1RW8

Crystal Structure of TGF-beta receptor I kinase with ATP site inhibitor

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.40 Å
  • R-Value Free: 0.291 
  • R-Value Work: 0.260 

wwPDB Validation   3D Report Full Report


This is version 1.2 of the entry. See complete history. 


Literature

Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.

Sawyer, J.S., Beight, D.W., Britt, K.S., Anderson, B.D., Campbell, R.M., Goodson Jr., T., Herron, D.K., Li, H.Y., McMillen, W.T., Mort, N., Parsons, S., Smith, E.C., Wagner, J.R., Yan, L., Zhang, F., Yingling, J.M.

(2004) Bioorg Med Chem Lett 14: 3581-3584

  • DOI: 10.1016/j.bmcl.2004.04.007
  • Primary Citation of Related Structures:  
    1RW8, 1PY5

  • PubMed Abstract: 

    • We have expanded our previously reported series of pyrazole-based inhibitors of the TGF-beta type I receptor kinase domain (TbetaR-I) to now include new 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole analogues. Limited examination of the SAR of this new series in both enzyme and cell based in vitro assays has revealed selectivity differences with respect to p38 MAP kinase (p38 MAPK) depending on the nature of the 'warhead' group on the dihydropyrrolopyrazole ring ...

    We have expanded our previously reported series of pyrazole-based inhibitors of the TGF-beta type I receptor kinase domain (TbetaR-I) to now include new 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole analogues. Limited examination of the SAR of this new series in both enzyme and cell based in vitro assays has revealed selectivity differences with respect to p38 MAP kinase (p38 MAPK) depending on the nature of the 'warhead' group on the dihydropyrrolopyrazole ring. As with our original pyrazole series, phenyl substituents tended to show greater selectivity against p38 MAPK than those comprised of the quinoline-4-yl moiety. We have also achieved co-crystallization and X-ray analysis of compounds 3 and 15, two potent examples of this new series, with the TbetaR-I receptor kinase domain.

    Organizational Affiliation: 

    Discovery Chemistry Research and Technology, The Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA. jss.dcrt@lilly.com



Macromolecules
Find similar proteins by: 
(by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
TGF-beta receptor type I A301Homo sapiensMutation(s): 0 
Gene Names: Tru, TGFBR1, ALK5, SKR4
EC: 2.7.1.37 (PDB Primary Data), 2.7.11.30 (UniProt)
Find proteins for P36897 (Homo sapiens)
Explore P36897 
Go to UniProtKB:  P36897
NIH Common Fund Data Resources
PHAROS:  P36897
GTEx:  ENSG00000106799
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
580
Query on 580
Download Ideal Coordinates CCD File 
A
3-(4-FLUOROPHENYL)-2-(6-METHYLPYRIDIN-2-YL)-5,6-DIHYDRO-4H-PYRROLO[1,2-B]PYRAZOLE
C18 H16 F N3
NBDZLUOYAAVYHF-UHFFFAOYSA-N		 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
580IC50:  1320   nM  BindingDB
580IC50:  175   nM  Binding MOAD
580IC50 :  175   nM  PDBBind
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.40 Å
  • R-Value Free: 0.291 
  • R-Value Work: 0.260 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 41.961α = 90
b = 84.961β = 90
c = 84.085γ = 90
Software Package:
Software NamePurpose
HKL-2000data collection
SCALEPACKdata scaling
AMoREphasing
CNSrefinement
HKL-2000data reduction

Structure Validation

View Full Validation Report


View more in-depth experimental data

Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2005-02-01
    Type: Initial release
  • Version 1.1: 2008-04-29
    Changes: Version format compliance
  • Version 1.2: 2011-07-13
    Changes: Version format compliance